Výběr nejlepšího režimu adjuvantní chemoterapie založené na trastuzumabu: měli bychom se vzdát .....
Výběr nejlepšího režimu adjuvantní chemoterapie založené na trastuzumabu: měli bychom se vzdát antracyklinů?
Harold J. Burstein, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Martine J. Piccart-Gebhart, Institut Jules Bordet, Brussels, Belgium
Edith A. Perez, Mayo Clinic, Jacksonville, FL
Gabriel N. Hortobagyi, MD Anderson Cancer Center, Houston, TX
Norman Wolmark, Allegheny General Hospital, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA
Kathy S. Albain, Loyola University Chicago Stritch School of Medicine, Maywood, IL
Larry Norton, Memorial Sloan-Kettering Cancer Center, New York, NY
Eric P. Winer, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY
LITERATURA
1. Perez EA, Romond EH, Suman VJ, et al: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373, 2011
2. Gianni L, Dafni U, Gelber RD, et al: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236-244, 2011
3. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
4. Spielmann M, Roché H, Delozier T, et al: Trastuzumab for patients with axillary node-positive breast cancer: Results of the FNCLCC-PACS 04 trial. J Clin Oncol 27:6129-6134, 2009
5. Gianni L, Eiermann W, Semiglazov V, et al: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377-384, 2010
6. Perez EA, Suman VJ, Davidson NE, et al: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 29:4491-4497, 2011
7. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
8. Bergstrom KA, Wang Z, Aksamit I, et al: Guideline adherence rates of chemotherapy treatment for breast cancer patients treated in U.S. community oncology practices. Presented at the 2010 American Society of Clinical Oncology Breast Cancer Symposium, Washington, DC, October 1-3, 2010
9. Bayraktar S, Gonzalez-Angulo AM, Lei X, et al: Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracyclinebased regimens for HER2-positive breast cancer. Cancer 118:2385–2393, 2012
10. Gennari A, Sormani MP, Pronzato P, et al: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 100:14-20, 2008
11. Hayes DF, Thor AD, Dressler LG, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506, 2007
12. Pegram MD, Konecny GE, O’Callaghan C, et al: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739-749, 2004
13. Valero V, Forbes J, Pegram MD, et al: Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): Two highly active therapeutic regimens. J Clin Oncol 29:146-156, 2011
14. Citron ML, Berry DA, Cirincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:431-439, 2003
15. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671, 2008
16. Press M, Sauter G, Boyce M, et al: Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracyclinebased chemotherapy. J Clin Oncol 29:859-867, 2011
17. Gianni L, Norton L, Wolmark N, et al: Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol 27:4798-4808, 2009
18. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2–overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005
19. Morris PG, Chen C, Steingart R, et al: Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res 17:3490-3499, 2011
DOI: 10.1200/JCO.2012.42.0695; publikováno online před tiskem na www.jco.org 21. května 2012
Celý článek najdete v časopise Journal of Clinical Oncology číslo 4/2012 strana 194
Zdroj: Journal of Clinical Oncology